<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297398</url>
  </required_header>
  <id_info>
    <org_study_id>SAR-202</org_study_id>
    <nct_id>NCT03297398</nct_id>
  </id_info>
  <brief_title>Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of different doses of OPK-88004&#xD;
      compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia&#xD;
      (BPH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study SAR-202 is a phase 2 multicenter, placebo-controlled, double-blind trial to evaluate&#xD;
      the effect of OPK-88004 doses (OPK-88004 15 mg, or OPK-88004 25 mg) on serum PSA compared to&#xD;
      placebo in men with BPH. Approximately 115 men with BPH will be enrolled in the study,&#xD;
      randomized 1:1:1 across three arms (placebo, OPK-88004 15 mg, or OPK-88004 25 mg). The trial&#xD;
      will be conducted at approximately up to 35 sites within the US.&#xD;
&#xD;
      The study duration for individual subjects will be up to 24 weeks and will include three&#xD;
      phases:&#xD;
&#xD;
        -  a screening period (up to 4 weeks, including 1-week washout if required),&#xD;
&#xD;
        -  a treatment period (16 weeks), and&#xD;
&#xD;
        -  a follow-up period (4 weeks) Subjects will be randomized and receive their first dose of&#xD;
           study drug at visit 2. They will begin the once daily oral dosing regimen and return&#xD;
           every 4 weeks to the study site during the 16-week treatment period. Assessments during&#xD;
           the study period will include vital signs, laboratory testing, weight, adverse events&#xD;
           (AEs), concomitant drugs, and study drug compliance. Efficacy assessments will include&#xD;
           serum PSA, LBM and fat mass by DXA scans, uroflowmetry parameters, PVR (by ultrasound),&#xD;
           and assessment of symptoms by IPSS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study terminated by sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in PSA (%) to Week 16</measure>
    <time_frame>16 weeks</time_frame>
    <description>The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
  </other_outcome>
  <other_outcome>
    <measure>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
  </other_outcome>
  <other_outcome>
    <measure>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
  </other_outcome>
  <other_outcome>
    <measure>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
  </other_outcome>
  <other_outcome>
    <measure>International Prostate Symptom Score- IPSS</measure>
    <time_frame>16 weeks</time_frame>
    <description>To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg, OPK-88004</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25,mg OPK-88004</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group-1 (15mg, OPK-88004)</intervention_name>
    <description>15mg, OPK-88004</description>
    <arm_group_label>Drug Group 1</arm_group_label>
    <other_name>Selective Androgen Receptor Modulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group-2 (25 mg,OPK-88004)</intervention_name>
    <description>25 mg,OPK-88004</description>
    <arm_group_label>Drug Group 2</arm_group_label>
    <other_name>Selective Androgen Receptor Modulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Inactive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects are eligible if they meet the following criteria:&#xD;
&#xD;
          1. Present with BPH-LUTS based on disease diagnostic criteria at visit 1&#xD;
&#xD;
          2. Are men aged 45 years or older at visit 1&#xD;
&#xD;
          3. Have prostate volume &gt;40 cm3 and &lt;80 cm3 assessed by TRUS at visit 1&#xD;
&#xD;
          4. Have a PSA &gt;1.5 and &lt;10.0 ng/mL at visit 1. This PSA blood draw must be performed at&#xD;
             least 1 week after any digital rectal exam (DRE) and/or transrectal ultrasound (TRUS)&#xD;
             procedures&#xD;
&#xD;
          5. Subjects with a PSA ≥4.0 and &lt;10.0 ng/mL must have documentation of a negative&#xD;
             histologic biopsy of carcinoma of the prostate within 12 months of screening (visit&#xD;
             1). For subjects aged ≤80 years and who have not undergone any invasive urological&#xD;
             procedure within 6 months, if biopsy has not been performed, then 4Kscore Test value&#xD;
             must be &lt;7.5% at visit 1&#xD;
&#xD;
          6. Have laboratory tests within normal limits (with the exception of total serum or free&#xD;
             testosterone). If laboratory test results are outside normal limits they are&#xD;
             determined to be not clinically significant at visit 1&#xD;
&#xD;
          7. Have not received prior treatment with 5-ARIs (finasteride, dutasteride) within the&#xD;
             past one year for any indication&#xD;
&#xD;
          8. Have not received herbal BPH preparations within 1 week of visit 1. If the subject is&#xD;
             currently on such treatment, a 1-week washout period will be required&#xD;
&#xD;
          9. Agree not to use 5-ARIs, herbal or experimental treatments for BPH, at any time during&#xD;
             the study. Subjects on daily PDE5i's, alpha-blockers or anticholinergic medications&#xD;
             for BPH should remain on a stable dose during the study, unless a change in dose is&#xD;
             medically warranted. Occasional-use PDE5i's for ED are permitted at a stable dose and&#xD;
             frequency, however should not be taken within 72 hours prior to a study visit&#xD;
&#xD;
         10. Agree to use an acceptable method of birth control during the study and for 60 days&#xD;
             after the last dose of IP, unless the female partner is postmenopausal. Postmenopausal&#xD;
             is defined as a female &gt;50 years of age and 12 months of amenorrhea, or surgically&#xD;
             postmenopausal&#xD;
&#xD;
         11. Are reliable and willing to make themselves available for the duration of the study,&#xD;
             and who will comply with the required study and dosing visits and abide by the&#xD;
             Clinical Research Site policy and procedure and study restrictions&#xD;
&#xD;
         12. Have given written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients will be excluded from study enrollment if they meet any of the following criteria&#xD;
        at visit 1:&#xD;
&#xD;
          1. History of any of the following pelvic conditions:&#xD;
&#xD;
               -  radical prostatectomy, pelvic surgery for removal of malignancy, or bowel&#xD;
                  resection&#xD;
&#xD;
               -  pelvic radiotherapy&#xD;
&#xD;
               -  any pelvic surgical procedure on the urinary tract, including transurethral&#xD;
                  resection of the prostate (TURP), penile implant surgery&#xD;
&#xD;
               -  lower urinary tract malignancy or trauma&#xD;
&#xD;
               -  pelvic surgery or any other pelvic procedure less than 6 months prior to visit 1&#xD;
&#xD;
          2. Lower urinary tract instrumentation (including prostate biopsy) within 6 weeks prior&#xD;
             to screening PSA blood draw&#xD;
&#xD;
          3. History of urinary retention or lower urinary tract (bladder) stones within 1 month of&#xD;
             visit 1&#xD;
&#xD;
          4. Minimally invasive procedures for BPH, such as prostatic stent, high intensity focused&#xD;
             ultrasound (HIFU), holmium laser enucleation of prostate (HoLEP), interstitial laser&#xD;
             coagulation (ILC), transurethral electroevaporation of the prostate (TUVP),&#xD;
             transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA),&#xD;
             photoselective vaporization (PVP), UroLift, within 6 weeks&#xD;
&#xD;
          5. Clinical evidence of urinary tract infection or urinary tract inflammation (including&#xD;
             prostatitis)&#xD;
&#xD;
          6. Intravesical obstruction (eg, intravesical median lobe of the prostate)&#xD;
&#xD;
          7. Current neurologic disease or condition associated with neurogenic bladder (eg,&#xD;
             Parkinson's disease, multiple sclerosis)&#xD;
&#xD;
          8. History of significant renal insufficiency, defined as receiving renal dialysis or&#xD;
             having an estimated creatinine clearance &lt;45 mL/min&#xD;
&#xD;
          9. Active hepatobiliary disease or serologic evidence of active hepatitis A, B, C,&#xD;
             hepatitis E or HIV&#xD;
&#xD;
         10. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2X the&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
         11. Glycosylated hemoglobin (HbA1c) &gt;9%&#xD;
&#xD;
         12. Hematocrit ≥50%&#xD;
&#xD;
         13. HDL-C &lt;35 mg/dL and LDL-C &gt;130 mg/dL&#xD;
&#xD;
         14. QTcB interval &gt;450 msec. For heart rates over 75, the ECG may be repeated after 5&#xD;
             minutes of resting quietly&#xD;
&#xD;
         15. Abnormality in ECG (eg, left bundle branch block, complete right bundle branch block,&#xD;
             or delayed intraventricular conduction with a QRS interval &gt;120 msec) that in the&#xD;
             opinion of the investigator places the subject at an unacceptable risk for study&#xD;
             participation, or subject has implanted pacemaker&#xD;
&#xD;
         16. History of any of the following cardiac/coronary conditions within 90 days:&#xD;
&#xD;
               -  history of myocardial infarction or coronary artery bypass graft&#xD;
&#xD;
               -  percutaneous coronary intervention&#xD;
&#xD;
               -  stroke&#xD;
&#xD;
         17. Any evidence of heart disease (NYHA ≥Class II, Appendix 4) within 6 months, or are&#xD;
             receiving treatment for congestive heart failure (CHF)&#xD;
&#xD;
         18. Any supraventricular or ventricular arrhythmia with uncontrolled ventricular response&#xD;
             (mean heart rate &gt;100 bpm) at rest despite medical therapy&#xD;
&#xD;
         19. Systolic blood pressure &gt;160 or &lt;90 mm Hg or diastolic blood pressure &gt;100 or &lt;50 mm&#xD;
             Hg as determined by a sitting measurement (if stress is suspected, retest up to two&#xD;
             times under basal conditions), or malignant hypertension&#xD;
&#xD;
         20. Have a history or presence of prostatic carcinoma, as well as any conditions that may&#xD;
             be exacerbated by androgenic medications such as (but not limited to) epilepsy,&#xD;
             seizures, convulsions, migraine or polycythemia&#xD;
&#xD;
         21. History of cancer within the previous 5 years, except for excised superﬁcial lesions&#xD;
             (such as basal cell carcinoma and squamous cell carcinoma of the skin)&#xD;
&#xD;
         22. History of drug, alcohol, or substance abuse within 6 months&#xD;
&#xD;
         23. Have an alcohol intake of ≥3 units/day or ≥14 units/week during the study (1 unit = 12&#xD;
             ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits)&#xD;
&#xD;
         24. Any condition that would interfere with subject's ability to provide informed consent&#xD;
             or comply with study instructions, would impair ability to perform the study&#xD;
             assessments, or would place subject at increased risk, or might confound the&#xD;
             interpretation of the study results&#xD;
&#xD;
         25. Current treatment with androgens, antiandrogens, estrogens, or anabolic steroids&#xD;
             within the prior 1 month. Any prior or current treatment with LHRH&#xD;
             agonists/antagonists&#xD;
&#xD;
         26. Current treatment with potent CYP3A4 inhibitors such as itraconazole or ritonavir&#xD;
&#xD;
         27. Have taken prescription or over-the-counter medications to promote weight loss within&#xD;
             the prior 3 months&#xD;
&#xD;
         28. Any prior use of OPK-88004 Allergic to any component of OPK-88004&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Militza Vera De Alba, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC - Valley Village</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APF Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Brooksville</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Boise</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <results_first_submitted>July 2, 2021</results_first_submitted>
  <results_first_submitted_qc>July 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03297398/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03297398/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo Group&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>OPK-88004 15 mg</title>
          <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
        </group>
        <group group_id="P3">
          <title>OPK-88004 25 mg</title>
          <description>25mg, OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Other</title>
          <description>Placebo Group&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Drug Group 1</title>
          <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
        </group>
        <group group_id="B3">
          <title>Drug Group 2</title>
          <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="6.52"/>
                    <measurement group_id="B2" value="64.5" spread="5.77"/>
                    <measurement group_id="B3" value="65.3" spread="6.01"/>
                    <measurement group_id="B4" value="64.6" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kilogram)</title>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.97" spread="16.937"/>
                    <measurement group_id="B2" value="95.31" spread="19.128"/>
                    <measurement group_id="B3" value="91.35" spread="13.564"/>
                    <measurement group_id="B4" value="93.88" spread="16.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (kilogram/meter^2)</title>
          <units>Kilogram/meter^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.17" spread="5.114"/>
                    <measurement group_id="B2" value="30.37" spread="5.286"/>
                    <measurement group_id="B3" value="29.36" spread="3.442"/>
                    <measurement group_id="B4" value="29.97" spread="4.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PSA (%) to Week 16</title>
        <description>The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PSA (%) to Week 16</title>
          <description>The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo</description>
          <units>Percentage of serum PSA change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="5.198"/>
                    <measurement group_id="O2" value="-1.48" spread="5.569"/>
                    <measurement group_id="O3" value="-15.44" spread="5.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks</title>
        <description>To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks</title>
          <description>To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass</description>
          <units>gram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline in Lean Body Mass (g) to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="439.62"/>
                    <measurement group_id="O2" value="1610.3" spread="489.45"/>
                    <measurement group_id="O3" value="1961.6" spread="522.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in Fat Mass (g) to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-198.2" spread="326.84"/>
                    <measurement group_id="O2" value="-1468.7" spread="373.06"/>
                    <measurement group_id="O3" value="-1491.3" spread="388.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)</title>
        <description>Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)</title>
          <description>Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
          <units>millilitre/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="3.810"/>
                    <measurement group_id="O2" value="0.61" spread="4.072"/>
                    <measurement group_id="O3" value="1.08" spread="4.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)</title>
        <description>Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)</title>
          <description>Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
          <units>millilitre/second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.475"/>
                    <measurement group_id="O2" value="-0.30" spread="0.509"/>
                    <measurement group_id="O3" value="0.15" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)</title>
        <description>Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)</title>
          <description>Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
          <units>millilitre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.12" spread="21.294"/>
                    <measurement group_id="O2" value="-2.28" spread="22.501"/>
                    <measurement group_id="O3" value="-29.12" spread="22.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)</title>
        <description>Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)</title>
          <description>Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16</description>
          <units>millilitre</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="10.365"/>
                    <measurement group_id="O2" value="17.63" spread="11.325"/>
                    <measurement group_id="O3" value="-15.19" spread="10.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>International Prostate Symptom Score- IPSS</title>
        <description>To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Other</title>
            <description>Placebo Group&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Drug Group 1</title>
            <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
          </group>
          <group group_id="O3">
            <title>Drug Group 2</title>
            <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score- IPSS</title>
          <description>To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)</description>
          <units>Total IPSS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="7.70"/>
                    <measurement group_id="O2" value="12.8" spread="6.21"/>
                    <measurement group_id="O3" value="14.2" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Other</title>
          <description>Placebo Group&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Drug Group 1</title>
          <description>15mg, OPK-88004&#xD;
Group-1 (15mg, OPK-88004): 15mg, OPK-88004</description>
        </group>
        <group group_id="E3">
          <title>Drug Group 2</title>
          <description>25,mg OPK-88004&#xD;
Group-2 (25 mg,OPK-88004): 25 mg,OPK-88004</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood testosterone free decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sperm concentration decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Apolipoprotein B increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The obligations of non-disclosure and non-use set forth in the confidentiality is 10 years after expiration of the agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>OPKO Health Inc</name_or_title>
      <organization>OPKO Health Inc</organization>
      <phone>3055754100</phone>
      <email>contact@opko.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

